AXIM Biotechnologies, Inc.
AXIM Biotechnologies, Inc.
Your view on AXIM
Overview
What the company does, where it operates, and who runs it.
About AXIM Biotechnologies, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Catalina Valencia
- Headquarters
- 6191 Cornerstone Court, East, San Diego, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Catalina Valencia
- Headquarters
- 6191 Cornerstone Court, East, San Diego, CA, US
AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and oncology.
The company is developing rapid diagnostic tests, which measure the levels of functional neutralizing antibodies that prevent SARS-CoV-2 from attaching to human cells; serological diagnostic test, which detect neutralizing antibodies that measure adaptive immune response to the SARS-CoV-2 virus; and tests for management of COVID-19 Patients to detect biomarkers related to inflammation.
It is also developing rapid quantitative tear tests for Matrix metalloproteinase-9, an inflammatory biomarker for dry eye disease; SBI-183, an anti-metastatic compound suppressing tumor cell growth and blocking metastasis; and SPX-1009, an anti-metastatic treatment to measure levels of quiescin sulfhydryl oxidase I.
The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for AXIM Biotechnologies, Inc., and the rating behind it. AXIM last traded at $0.01; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for AXIM Biotechnologies, Inc.. Starting points for AXIM Biotechnologies, Inc.: beta -0.64 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for AXIM Biotechnologies, Inc.. AXIM Biotechnologies, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for AXIM Biotechnologies, Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for AXIM Biotechnologies, Inc.. AXIM Biotechnologies, Inc. has reported as a listed company since 2014. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
AXIM Biotechnologies, Inc. valued side by side against its closest peers. AXIM Biotechnologies, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold AXIM Biotechnologies, Inc., and how their positions are changing. At a $3.7M market value, institutional positions materially move AXIM Biotechnologies, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by AXIM Biotechnologies, Inc. executives and directors. Shares of AXIM Biotechnologies, Inc. have traded between $0.0030 and $0.03 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming AXIM Biotechnologies, Inc.. AXIM Biotechnologies, Inc. is a $3.7M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming AXIM Biotechnologies, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for AXIM Biotechnologies, Inc.. Coverage tracks AXIM Biotechnologies, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.